New Repatha evolocumab Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDLC Levels

THOUSAND OAKS Calif. Aug. 28 2017 PRNewswire Amgen NASDAQAMGN today announced a new analysis from the Repatha evolocumab cardiovascular outcomes study FOURIER that showed a statistically significant relationship between lower achieved lowdensity lipoprot...